NRX Pharmaceuticals (NRXP) Other Non-Current Assets (2020 - 2026)
NRX Pharmaceuticals' (NRXP) quarterly Other Non-Current Assets came in at $276000.0 in Q1 2026, down 17.37% year-on-year from $334000.0 in Q1 2025, and up 9.09% on a QoQ basis from $253000.0 in Q4 2025.
NRX Pharmaceuticals (NRXP) Other Non-Current Assets (2020 - 2026) Analysis & Trends
NRX Pharmaceuticals (NRXP) has 7 years of Other Non-Current Assets data on file, last reported at $276000.0 in Q1 2026.
- On a quarterly basis, Other Non-Current Assets fell 17.37% year-over-year to $276000.0 in Q1 2026; TTM through Mar 2026 was $276000.0, a 17.37% decrease from a year earlier, with the FY2025 full-year figure at $253000.0, down 25.37% from the prior year.
- Other Non-Current Assets for Q1 2026 stood at $276000.0, up from $253000.0 in the prior quarter.
- Over the last five years, Other Non-Current Assets for NRXP reached as high as $441000.0 in Q1 2024 and fell as low as $17000.0 in Q1 2022.
- Historically, Other Non-Current Assets has averaged $203000.0 across 5 years, with a median of $248000.0 in 2025.
- Across the five-year window, Other Non-Current Assets jumped 1952.38% in 2023 and plunged 35.42% in 2025, its largest moves.
- Year by year, Other Non-Current Assets stood at $21000.0 in 2022, then soared by 1952.38% to $431000.0 in 2023, then decreased by 21.35% to $339000.0 in 2024, then slipped by 25.37% to $253000.0 in 2025, then gained by 9.09% to $276000.0 in 2026.
- Per Business Quant data, the three most recent Other Non-Current Assets figures were $276000.0 in Q1 2026, $253000.0 in Q4 2025, and $243000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 65,899.61 Bn | 65,899.33 Bn | - | 1.02 Mn |
| 2 | Nanobiotix | 1,933.82 Bn | 1,933.76 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | 60,000.00 |
| 4 | BeOne Medicines | 471.67 Bn | 466.88 Bn | 1.35 Bn | 104.24 Mn |
| 5 | Vertex Pharmaceuticals | 122.32 Bn | 115.07 Bn | 2.59 Bn | 1.26 Bn |
| 6 | Regeneron Pharmaceuticals | 70.04 Bn | 61.29 Bn | 3.31 Bn | 2.13 Bn |
| 7 | Belite Bio | 62.06 Bn | 62.06 Bn | - | 289.41 Mn |
| 8 | Argenx Se | 55.93 Bn | 50.74 Bn | 1.41 Bn | 124.00 Mn |
| 9 | Alnylam Pharmaceuticals | 37.55 Bn | 34.54 Bn | 959.66 Mn | 63.55 Mn |
| 10 | NRX Pharmaceuticals | 117.34 Mn | 110.64 Mn | 437,000.00 | 276,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 276,000.00 |
| Dec 31, 2025 | 253,000.00 |
| Sep 30, 2025 | 243,000.00 |
| Jun 30, 2025 | 248,000.00 |
| Mar 31, 2025 | 334,000.00 |
| Dec 31, 2024 | 339,000.00 |
| Sep 30, 2024 | 356,000.00 |
| Jun 30, 2024 | 384,000.00 |
| Mar 31, 2024 | 441,000.00 |
| Dec 31, 2023 | 431,000.00 |
| Sep 30, 2023 | 21,000.00 |
| Jun 30, 2023 | 21,000.00 |
| Mar 31, 2023 | 24,000.00 |
| Dec 31, 2022 | 21,000.00 |
| Sep 30, 2022 | 23,000.00 |
| Jun 30, 2022 | 19,000.00 |
| Mar 31, 2022 | 17,000.00 |
| Dec 31, 2021 | 15,000.00 |
| Sep 30, 2021 | 15,921.00 |
| Jun 30, 2021 | 12,730.00 |